Bioburden Testing
for Peptides

Bioburden testing quantifies the number of viable microorganisms present in or on a sample. For peptide drug substances and intermediates, this means determining whether bacteria, yeast, or mold have been introduced during synthesis, purification, handling, or storage. The test is a fundamental quality control checkpoint that ensures microbial contamination is detected before material moves into formulation, animal studies, or clinical manufacturing.

Contamination can enter at any point in the peptide supply chain—during handling in non-controlled environments, from contaminated equipment during lyophilization, or during reconstitution and aliquoting in a laboratory setting. Peptide solutions in particular are vulnerable because many peptides are reconstituted in aqueous buffers that can support microbial growth. Without bioburden data, you risk carrying contaminated material forward into expensive downstream processes.

The streak plate method is a straightforward, cost-effective approach to bioburden assessment. A defined volume of the peptide sample (or a rinse from a lyophilized vial) is streaked across the surface of nutrient agar plates—typically tryptic soy agar (TSA) for bacteria and Sabouraud dextrose agar (SDA) for fungi. The plates are incubated at 30–35 °C for bacteria and 20–25 °C for fungi, then inspected for colony growth at defined time points (typically 3 and 5 days for bacteria, 5 and 7 days for fungi).

Colony counts are expressed as colony-forming units (CFU) per unit of sample. For peptide drug substances, typical acceptance criteria in early development are fewer than 100 CFU/mL, though the specific limit depends on the intended route of administration and stage of development. Parenteral products require much tighter bioburden limits than topical formulations. The test also provides qualitative information—colony morphology can suggest the class of organism present, guiding further identification if needed.

A clean plate (zero CFU) confirms that your peptide material is free of detectable microbial contamination under the test conditions. Low-level counts (1–10 CFU) may indicate environmental contamination introduced during handling rather than a systemic issue with the peptide supply. High counts or the presence of objectionable organisms (such as Pseudomonas, Staphylococcus, or Enterobacteriaceae) are red flags that require root-cause investigation before proceeding.

Bioburden results should be interpreted alongside knowledge of how the peptide was manufactured, stored, and handled. A peptide freshly synthesized under controlled conditions that shows unexpected bioburden may indicate a problem with reconstitution water, storage containers, or handling practices. Tracking bioburden over time as part of a stability program reveals whether microbial growth is occurring in storage, which can inform preservative selection and storage condition specifications.